Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.3.

EBIT: As of FY2026 Q2, the actual value is USD -32.78 M.

Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2026, on August 4, 2026. Specific financial metrics such as segment revenue, net income, gross margin, operating profit, operating costs, cash flow, or any forward-looking guidance are not available within the provided reference material.

Cash and Investments

Larimar Therapeutics, Inc. reported $156.3 million in cash and investments as of June 30, 2026.

Cash Runway

Larimar Therapeutics, Inc. projects its cash runway to extend into Q3 2027.

Operational Metrics (Nomlabofusp Clinical Development)

• Clinical Studies Completed: Data from 4 successfully completed studies (Phase 1 SAD and MAD, Phase 2 dose-exploration, and adolescent PK) are available.
• Long-Term Open Label Study: As of June 2026 data release, 76 participants have been enrolled, with over 10,000 doses administered. 66 participants received at least one dose, 43 participants were dosed, and 22 remain active, with a maximum duration of over 800 days.
• Discontinuations from OL Study: 21 participants discontinued from the Open Label study. This included 10 due to anaphylaxis (9 with prior nomlabofusp exposure), 3 due to generalized urticaria, 3 due to other adverse events, and 5 for non-treatment related reasons (primarily logistical). All participants who experienced anaphylaxis recovered without sequelae.
• Dosing Duration: 13 participants completed 1 year of dosing, 7 completed 18 months, and 3 completed 2 years.
• Tissue FXN Levels: The study showed sustained increases in tissue FXN levels. The percentage of participants achieving skin FXN levels in the range of asymptomatic heterozygous carriers increased from 4% (¹⁄₂₇) at baseline to 100% (⁹⁄₉) at 1 year and 100% (³⁄₃) at 18 months. Mean absolute skin FXN levels increased from 3.7 at baseline to 12.1 at 1 year and 10.7 at 18 months.
• Clinical Outcomes (mFARS): At 1 year, there was a 2.6-point mFARS advantage when nomlabofusp treatment was compared to a FACOMS reference group. At 18 months, this advantage increased to a 4.6-point mFARS advantage. The mean change from baseline in mFARS was -1.0 at 1 year (n=13) and -2.3 at 18 months (n=7).
• Clinical Outcomes (FARS-ADL): The mean change from baseline in FARS-ADL was -1.1 at 1 year (n=13) and -0.3 at 18 months (n=7).
• Clinical Outcomes (9-HPT Dominant Hand): The mean change from baseline in 9-HPT Dominant Hand was -15.6 at 1 year (n=12) and -11.8 at 18 months (n=7).
• Clinical Outcomes (MFIS): The mean change from baseline in MFIS was -5.2 at 1 year (n=13) and 0.6 at 18 months (n=7).
• Safety Profile: Nomlabofusp is generally well-tolerated long-term, with most common adverse events being mild to moderate injection site reactions that decreased over time.
• Regulatory Designations: Nomlabofusp has been awarded Breakthrough Therapy Designation, Rare Pediatric Disease Designation (US), Orphan Drug Designation (US & EU), Fast Track Designation (US), PRIME Designation (EU), ILAP (UK), and was selected for the START Pilot Program.
• Market Exclusivity: Nomlabofusp is expected to be eligible for 12 years of market exclusivity in the US and at least 10 years in the EU upon approval.

Outlook / Guidance

Larimar Therapeutics, Inc. initiated a rolling Biologics License Application (BLA) submission in June 2026, with the remaining modules expected in the second half of 2026, targeting a US launch in mid-2027 if approved. The company anticipates dosing the first patient in a global confirmatory Phase 3 study in Q3 2026 and plans to pursue approvals in the EU, UK, Canada, and Australia throughout 2027-2028. Larimar Therapeutics, Inc. expects to be eligible for a rare pediatric disease priority review voucher.